Haemonetics Reports Q3 Earnings, Meets Analyst Expectations
BOSTON--(BUSINESS WIRE)--Haemonetics Corp. (HAE) announced third-quarter fiscal 2023 net income of $37.5 million, or $0.74 per share. Adjusted earnings per share reached $1.19.
Analysts had anticipated earnings of $1.19 per share. Revenue for the quarter totaled $348.5 million, slightly below the consensus estimate of $353.1 million from four analysts surveyed by Zacks Investment Research.
The company, which provides blood management systems, projects full-year earnings between $4.50 and $4.70 per share.